RSS Feeds
Search

Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..10 of 10 - per page
Order by
Cellophil™ Biomedical Polymers - New and superior biomedical polymers for drug delivery and new standards in the medical device industry
Cellophil™ is a platform of novel polymers based on amino-acid groups. The platform polymers show superior biocompatibility and can be loaded with drugs for controlled release. More
Product enhancement of small and large molecules in a range of dosage forms
Proprietary supercritical fluid (SCF) technology to improve bioavailability, enhance stability and optimise drug delivery for small and large molecules in a range of dosage forms. More
Esmolol 100mg/10ml vial
Ultrashort acting beta blocker Esmolol for use in anesthesia, intensive care, cardiology and internal medicine. More
Optimised pulmonary and nasal therapies using supercritical fluid (SCF) particle engineering
Supercritical fluid crystal and particle engineering to form particles with strong aerodynamic performance and exceptional size uniformity for optimised pulmonary/nasal delivery More
Tackling challenges of poor solubility
Enhancing the dissolution performance of small and large molecules in a range of dosage forms More
VM202 / VM501 / VM206 / PG102
DNA-Based Therapeutic Angiogenesis / Protein Therapeutic for Thrombocytopenia / Therapeutic Cancer Vaccine Targeting HER2/neu / Hardy Kiwi Extract for Immune Hypersensitivity More
Stabilisation and rapid reconstitution of biopharmaceuticals
Improving the reconstitution and increasing the stability of biomolecules using supercritical fluid (SCF) processing More
Esmolol 2500 mg/10ml ampoule
Ultrashort acting beta blocker Esmolol for use in anesthesia, intensive care, cardiology and internal medicine. More
Second Generation Nitric Oxide-releasing Non-steroidal Anti-inflammatory Drugs Possessing a Diazeniumdiolate Group (NONO-NSAIDs)
Design, synthesis and biological evaluation of novel NO-releasing NSAIDs possessing a N-diazen-1-ium-1,2-diolate (NONOate), which offers additional advantages compared with organic nitrate-based NO-NSAIDs More
Cripto-1 as a Biomarker for Cardiac Ischemia
Cripto-1 is overexpressed in infarcted myocardial tissue More
Displaying 1..10 of 10 - per page
Order by

Related Reports

Market Research Reports provided by reports.iptechex.com
Failure of TAK442 to Meet the Primary End-point in a Phase II Study Underlines the Challenging Clinical Development Environment for Anticoagulants in Acute Coronary Syndromes
Nov 2010 - 5 pages - $500
Acute Coronary Syndromes Therapy Area Pipeline Report
Nov 2010 - 329 pages - $1,495
Acute Coronary Syndromes - Pipeline Review, Q1 2011
Feb 2011 - 62 pages - $500
Epidemiology: Acute Coronary Syndrome - Now affecting primarily the oldest populations
Jul 2011 - 46 pages - $3,800
Acute Coronary Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Dec 2010 - 49 pages - $2,000
Cyclacel Pharmaceuticals Inc. - Product Pipeline Review - Q4 2010
Nov 2010 - 44 pages - $500
Acute Coronary Syndrome - Pipeline Review, H2 2011
Sep 2011 - 106 pages - $500
Innovations in Cardiovascular Disease Management
May 2007 - 183 pages - $2,875
Stentys, S.A.S. - Medical Equipment - Deals and Alliances Profile
Mar 2011 - 28 pages - $250
The Future of Cardiovascular Diagnostics: Impact of technological advances on growth opportunities and future market outlook
Mar 2010 - 180 pages - $3,835
More Related Market Research Reports >>>

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us